Quality indicators for colorectal cancer surgery and care according to patient-, tumor-, and hospital-related factors

BMC Cancer

Eric Rullier⁶  Jean-Louis Renaud-Salis¹  Dominique Auby⁷  Gaëlle Coureau³  Anne Jaffré⁸  Elodie Pinon¹  Geneviève Belleannée⁴  Yves Bécouarn²  Simone Mathoulin-Pélissier⁵ 

[1]Réseau de Cancérologie d’Aquitaine, Bordeaux, France

[2]Department of Medical Oncology, Institut Bergonié, CRLCC, Bordeaux, France

[3]Cancer register for Gironde, Bordeaux, France

[4]Department of Pathology, Hopital du Haut-Lévêque, CHU, Bordeaux, France

[5]Université Bordeaux Segalen, 146 rue Léo Saignat, Bordeaux, France

[6]Department of Surgery, Hôpital Saint André, CHU, Bordeaux, France

[7]Department of Medicine, Centre Hospitalier Général, Libourne, France

[8]Clinical and Epidemiological Research Unit, Institut Bergonié CRLCC, Bordeaux, France

关键词: Medical practice;    Lymph node evaluation;    Colorectal cancer;    Cancer care organization;    Cancer care;   

Others  :  1080310
DOI  :  10.1186/1471-2407-12-297

 received in 2011-12-13, accepted in 2012-07-19,  发布年份 2012

【 摘 要 】

Background

Colorectal cancer (CRC) care has improved considerably, particularly since the implementation of a quality of care program centered on national evidence-based guidelines. Formal quality assessment is however still needed. The aim of this research was to identify factors associated with practice variation in CRC patient care.

Methods

CRC patients identified from all cancer centers in South-West France were included. We investigated variations in practices (from diagnosis to surgery), and compliance with recommended guidelines for colon and rectal cancer. We identified factors associated with three colon cancer practice variations potentially linked to better survival: examination of ≥12 lymph nodes (LN), non-use and use of adjuvant chemotherapy for stage II and stage III patients, respectively.

Results

We included 1,206 patients, 825 (68%) with colon and 381 (32%) with rectal cancer, from 53 hospitals. Compliance was high for resection, pathology report, LN examination, and chemotherapy use for stage III patients. In colon cancer, 26% of stage II patients received adjuvant chemotherapy and 71% of stage III patients. 84% of stage US T3T4 rectal cancer patients received pre-operative radiotherapy. In colon cancer, factors associated with examination of ≥12 LNs were: lower ECOG score, advanced stage and larger hospital volume; factors negatively associated were: left sided tumor location and one hospital district. Use of chemotherapy in stage II patients was associated with younger age, advanced stage, emergency setting and care structure (private and location); whereas under-use in stage III patients was associated with advanced age, presence of comorbidities and private hospitals.

Conclusions

Although some changes in practices may have occurred since this observational study, these findings represent the most recent report on practices in CRC in this region, and offer a useful methodological approach for assessing quality of care. Guideline compliance was high, although some organizational factors such as hospital size or location influence practice variation. These factors should be the focus of any future guideline implementation.

【 授权许可】

   
2012 Mathoulin-Pelissier et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Belot A, Grosclaude P, Bossard N, Jougla E, Benhamou E, Delafosse P, et al.: Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique 2008, 56:159-175.
• [2]Kanavos P, Schurer W: The dynamics of colorectal cancer management in 17 countries. Eur J Health Econ 2010, 10(Suppl 1):S115-S129.
• [3]Augestad KM, Lindsetmo RO, Stulberg J, Reynolds H, Senagore A, Champagne B, et al.: International preoperative rectal cancer management: staging, neoadjuvant treatment, and impact of multidisciplinary teams. World J Surg 2010, 34:2689-2700.
• [4]Bouhier K, Maurel J, Lefevre H, Bouin M, Arsene D, Launoy G: Changing practices for diagnosis and treatment of colorectal cancer in Calvados: 1990-1999. Gastroenterol Clin Biol 2004, 28:371-376.
• [5]Phelip JM, Launoy G, Colonna M, Grosclaude P, Velten M, Danzon A, et al.: Regional variations in management of rectal cancer in France. Gastroenterol Clin Biol 2004, 28:378-383.
• [6]Phelip JM, Grosclaude P, Launoy G, Colonna M, Danzon A, Velten M, et al.: Are there regional differences in the management of colon cancer in France? Eur J Cancer Prev 2005, 14:31-37.
• [7]Wennberg J: Time to tackle unwarranted variations in practice. BMJ 2011, 342:d1513.
• [8]Grimshaw JM, Russell IT: Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993, 342:1317-1322.
• [9]Wennekes L, Ottevanger PB, Raemaekers JM, Schouten HC, de Kok MW, Punt CJ: et al. Development and measurement of guideline-based indicators for patients with non-Hodgkin's lymphoma, J Clin Oncol; 2011.
• [10]Steimle S: French government launches National Cancer Institute. J Natl Cancer Inst 2005, 97:1116-1117.
• [11]American Society of Clinical Oncology, National Comprehensive Cancer Network: ASCO/NCCN quality measures. Breast and colorectal cancers 2011. http://www.asco.org/ASCO/Downloads/Cancer%20Policy%20and%20Clinical%20Affairs/NCCN/ASCO%20NCCN%20Quality%20Measures%20table%20web%20posting%20with%20CoC%200507.pdf webcite
• [12]Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA: Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 2007, 99:433-441.
• [13]Wong SL, Ji H, Hollenbeck BK, Morris AM, Baser O, Birkmeyer JD: Hospital lymph node examination rates and survival after resection for colon cancer. JAMA 2007, 298:2149-2154.
• [14]Phelip JM, Molinie F, Delafosse P, Launoy G, Tretarre B, Bara S, et al.: A population-based study of adjuvant chemotherapy for stage-II and -III colon cancers. Gastroenterol Clin Biol 2010, 34:144-149.
• [15]Prosnitz RG, Patwardhan MB, Samsa GP, Mantyh CR, Fisher DA, McCrory DC, et al.: Quality measures for the use of adjuvant chemotherapy and radiation therapy in patients with colorectal cancer: a systematic review. Cancer 2006, 107:2352-2360.
• [16]Wong SL, Birkmeyer JD: Lymph node examination rate, survival rate, and quality of care in colon cancer. JAMA 2008, 299:897-898.
• [17]Hosmer DW, Lemeshow S: Applied logistic regression. John Wiley and Sons, New York; 1989.
• [18]Mitton N, Colonna M, Trombert B, Olive F, Gomez F, Iwaz J, et al.: A Suitable Approach to Estimate Cancer Incidence in Area without Cancer Registry. J Cancer Epidemiol 2011, 2011:418968.
• [19]Cronin DP, Harlan LC, Potosky AL, Clegg LX, Stevens JL, Mooney MM: Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol 2006, 101:2308-2318.
• [20]Jessup JM, Stewart A, Greene FL, Minsky BD: Adjuvant Chemotherapy for Stage III Colon Cancer: Implications of Race/Ethnicity, Age, and Differentiation. JAMA 2005, 294:2703-2711.
• [21]Lin C, Charlton ME, Meza JL, Enke CA, Loberiza FR: Temporal and regional variations in the use of preoperative radiation therapy for rectal cancer. Am J Clin Oncol 2010, 33:443-447.
• [22]Baxter NN, Virnig DJ, Rothenberger DA, Morris AM, Jessurun J, Virnig BA: Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst 2005, 97:219-225.
• [23]Bilimoria KY, Stewart AK, Palis BE, Bentrem DJ, Talamonti MS, Ko CY: Adequacy and importance of lymph node evaluation for colon cancer in the elderly. J Am Coll Surg 2008, 206:247-254.
• [24]Wichmann MW, Muller C, Meyer G, Strauss T, Hornung HM, Lau-Werner U, et al.: Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer. Arch Surg 2002, 137:206-210.
• [25]Morcos B, Baker B, Al MM, Haddad H, Hashem S: Lymph node yield in rectal cancer surgery: effect of preoperative chemoradiotherapy. Eur J Surg Oncol 2010, 36:345-349.
• [26]Bilimoria KY, Stewart AK, Edge SB, Ko CY: Lymph node examination rate, survival rate, and quality of care in colon cancer. JAMA 2008, 299:896-898.
• [27]Peters E, Nagtegaal ID: van d, V, van Krieken JH. Lymph node examination rate, survival rate, and quality of care in colon cancer. JAMA 2008, 299:896-897.
• [28]Quipourt V, Jooste V, Cottet V, Faivre J, Bouvier AM: Comorbidities alone do not explain the undertreatment of colorectal cancer in older adults: a French population-based study. J Am Geriatr Soc 2011, 59:694-698.
• [29]Keating NL, Landrum MB, Klabunde CN, Fletcher RH, Rogers SO, Doucette WR, et al.: Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? J Clin Oncol 2008, 20(26):2532-2537.
• [30]Winget M, Hossain S, Yasui Y, Scarfe A: Characteristics of patients with stage III colon adenocarcinoma who fail to receive guideline-recommended treatment. Cancer 2010, 116:4849-4856.
• [31]Figueredo A, Coombes ME, Mukherjee S: Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev 2008, CD005390.
• [32]O'Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, et al.: Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 2011, 29:3381-3388.
• [33]Leonardi MJ, McGory ML, Ko CY: Quality of care issues in colorectal cancer. Clin Cancer Res 2007, 13:6897s-6902s.
• [34]Bilimoria KY, Bentrem DJ, Stewart AK, Talamonti MS, Winchester DP, Russell TR, et al.: Lymph node evaluation as a colon cancer quality measure: a national hospital report card. J Natl Cancer Inst 2008, 100:1310-1317.
• [35]Alter E, Phelip JM, Guilhot JN, Matysiak M, Vermorel M, Roblin X: Adjuvant chemotherapy for stage II colon cancer: influence of care structures' characteristics on a controversial clinical practice. Eur J Gastroenterol Hepatol 2007, 19:995-1001.
• [36]Bouvier AM, Bauvin E, Danzon A, Grosclaude P, Delafosse P, Buemi A, et al.: Place of multidisciplinary consulting meetings and clinical trials in the management of colorectal cancer in France in 2000. Gastroenterol Clin Biol 2007, 31:286-291.
• [37]Morris E, Haward RA, Gilthorpe MS, Craigs C, Forman D: The impact of the Calman-Hine report on the processes and outcomes of care for Yorkshire's colorectal cancer patients. Br J Cancer 2006, 95:979-985.
• [38]Carsin AE, Sharp L, Cronin-Fenton DP, Ceilleachair AO, Comber H: Inequity in colorectal cancer treatment and outcomes: a population-based study. Br J Cancer 2008, 99:266-274.
• [39]Dejardin O, Herbert C, Velten M, Buemi A, Menegoz F, Maarouf N, et al.: Social and geographical factors influencing the delay in treatment for colorectal cancer. Br J Cancer 2004, 91:1751-1752.
• [40]Dejardin O, Ruault E, Jooste V, Pornet C, Bouvier V, Bouvier AM, et al.: Volume of surgical activity and lymph node evaluation for patients with colorectal cancer in France. Dig Liver Dis 2012, 44:261-267.
• [41]Hodgson DC, Fuchs CS, Ayanian JZ: Impact of Patient and Provider Characteristics on the Treatment and Outcomes of Colorectal Cancer. J Natl Cancer Inst 2001, 93:501-515.
• [42]Birkmeyer JD, Sun Y, Wong SL, Stukel TA: Hospital volume and late survival after cancer surgery. Ann Surg 2007, 245:777-783.
• [43]McCarthy M, Datta P, Sherlaw-Johnson C, Coleman M, Rachet B: Is the performance of cancer services influenced more by hospital factors or by specialization? J Public Health (Oxf) 2008, 30:69-74.
• [44]Petrelli NJ: Not just another article on cancer surgery volume and patient outcomes. J Clin Oncol 2008, 26:4530-4531.
• [45]Ministère de la santé et des solidarités: Seuils d'activité minimale annuelle applicables à l'activité de soins de traitement du cancer. http://www.e-cancer.fr/index.php?option=com_content&view=article&id=2622&Itemid=2426 29-3-2007 webcite